Uncategorized
Iconic Therapeutics raises $20 million for AMD protein therapy
Iconic Therapeutics completed a $20 million series B-1 equity financing to fund a clinical study of a recombinant human chimeric protein therapeutic that may treat age-related macular degeneration, according to a press release. MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures were involved in the round of financing.